Literature DB >> 26001956

TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis.

Anny Shai1, David Dankort1, Joseph Juan1, Shon Green1, Martin McMahon2.   

Abstract

Lung carcinogenesis is a multistep process in which normal lung epithelial cells are converted to cancer cells through the sequential acquisition of multiple genetic or epigenetic events. Despite the utility of current genetically engineered mouse (GEM) models of lung cancer, most do not allow temporal dissociation of the cardinal events involved in lung tumor initiation and cancer progression. Here we describe a novel two-switch GEM model for BRAF(V600E)-induced lung carcinogenesis allowing temporal dissociation of these processes. In mice carrying a Flp recombinase-activated allele of Braf (Braf(FA)) in conjunction with Cre-regulated alleles of Trp53, Cdkn2a, or c-MYC, we demonstrate that secondary genetic events can promote bypass of the senescence-like proliferative arrest displayed by BRAF(V600E)-induced lung adenomas, leading to malignant progression. Moreover, restoring or activating TP53 in cultured BRAF(V600E)/TP53(Null) or BRAF(V600E)/INK4A-ARF(Null) lung cancer cells triggered a G1 cell-cycle arrest regardless of p19(ARF) status. Perhaps surprisingly, neither senescence nor apoptosis was observed upon TP53 restoration. Our results establish a central function for the TP53 pathway in restricting lung cancer development, highlighting the mechanisms that limit malignant progression of BRAF(V600E)-initiated tumors. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26001956      PMCID: PMC4526430          DOI: 10.1158/0008-5472.CAN-14-3701

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  54 in total

Review 1.  Blinded by the Light: The Growing Complexity of p53.

Authors:  Karen H Vousden; Carol Prives
Journal:  Cell       Date:  2009-05-01       Impact factor: 41.582

2.  Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.

Authors:  Jianjiong Gao; Bülent Arman Aksoy; Ugur Dogrusoz; Gideon Dresdner; Benjamin Gross; S Onur Sumer; Yichao Sun; Anders Jacobsen; Rileen Sinha; Erik Larsson; Ethan Cerami; Chris Sander; Nikolaus Schultz
Journal:  Sci Signal       Date:  2013-04-02       Impact factor: 8.192

3.  Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model.

Authors:  Christin E Burd; Jessica A Sorrentino; Kelly S Clark; David B Darr; Janakiraman Krishnamurthy; Allison M Deal; Nabeel Bardeesy; Diego H Castrillon; David H Beach; Norman E Sharpless
Journal:  Cell       Date:  2013-01-17       Impact factor: 41.582

Review 4.  p53 mutations in cancer.

Authors:  Patricia A J Muller; Karen H Vousden
Journal:  Nat Cell Biol       Date:  2013-01       Impact factor: 28.824

5.  A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice.

Authors:  Adam J Dupuy; Laura M Rogers; Jinsil Kim; Kishore Nannapaneni; Timothy K Starr; Pentao Liu; David A Largaespada; Todd E Scheetz; Nancy A Jenkins; Neal G Copeland
Journal:  Cancer Res       Date:  2009-10-06       Impact factor: 12.701

6.  A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis.

Authors:  M Kracikova; G Akiri; A George; R Sachidanandam; S A Aaronson
Journal:  Cell Death Differ       Date:  2013-01-11       Impact factor: 15.828

7.  Oncogene-dependent control of miRNA biogenesis and metastatic progression in a model of undifferentiated pleomorphic sarcoma.

Authors:  Jeffrey K Mito; Hooney D Min; Yan Ma; Jessica E Carter; Brian E Brigman; Leslie Dodd; David Dankort; Martin McMahon; David G Kirsch
Journal:  J Pathol       Date:  2012-11-20       Impact factor: 7.996

8.  Stage-specific sensitivity to p53 restoration during lung cancer progression.

Authors:  David M Feldser; Kamena K Kostova; Monte M Winslow; Sarah E Taylor; Chris Cashman; Charles A Whittaker; Francisco J Sanchez-Rivera; Rebecca Resnick; Roderick Bronson; Michael T Hemann; Tyler Jacks
Journal:  Nature       Date:  2010-11-25       Impact factor: 49.962

9.  Selective activation of p53-mediated tumour suppression in high-grade tumours.

Authors:  Melissa R Junttila; Anthony N Karnezis; Daniel Garcia; Francesc Madriles; Roderik M Kortlever; Fanya Rostker; Lamorna Brown Swigart; David M Pham; Youngho Seo; Gerard I Evan; Carla P Martins
Journal:  Nature       Date:  2010-11-25       Impact factor: 49.962

Review 10.  PUMA, a critical mediator of cell death--one decade on from its discovery.

Authors:  Paweł Hikisz; Zofia M Kiliańska
Journal:  Cell Mol Biol Lett       Date:  2012-09-20       Impact factor: 5.787

View more
  9 in total

1.  TFAP2C promotes lung tumorigenesis and aggressiveness through miR-183- and miR-33a-mediated cell cycle regulation.

Authors:  J Kang; W Kim; S Lee; D Kwon; J Chun; B Son; E Kim; J-M Lee; H Youn; B Youn
Journal:  Oncogene       Date:  2016-09-05       Impact factor: 9.867

2.  p53 loss does not permit escape from BrafV600E-induced senescence in a mouse model of lung cancer.

Authors:  S Garnett; K L Dutchak; R V McDonough; D Dankort
Journal:  Oncogene       Date:  2017-07-24       Impact factor: 9.867

3.  Context-Dependent Effects of Amplified MAPK Signaling during Lung Adenocarcinoma Initiation and Progression.

Authors:  Michelle Cicchini; Elizabeth L Buza; Kyra M Sagal; A Andrea Gudiel; Amy C Durham; David M Feldser
Journal:  Cell Rep       Date:  2017-02-21       Impact factor: 9.423

4.  FoxA1 and FoxA2 control growth and cellular identity in NKX2-1-positive lung adenocarcinoma.

Authors:  Grace Orstad; Gabriela Fort; Timothy J Parnell; Alex Jones; Chris Stubben; Brian Lohman; Katherine L Gillis; Walter Orellana; Rushmeen Tariq; Olaf Klingbeil; Klaus Kaestner; Christopher R Vakoc; Benjamin T Spike; Eric L Snyder
Journal:  Dev Cell       Date:  2022-07-13       Impact factor: 13.417

Review 5.  Nucleolus-derived mediators in oncogenic stress response and activation of p53-dependent pathways.

Authors:  Dariusz Stępiński
Journal:  Histochem Cell Biol       Date:  2016-05-03       Impact factor: 4.304

6.  A Transgenic MMTV-Flippase Mouse Line for Molecular Engineering in Mammary Gland and Breast Cancer Mouse Models.

Authors:  Fabiana Lüönd; Ruben Bill; Andrea Vettiger; Heide Oller; Pawel Pelczar; Gerhard Christofori
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-09-12       Impact factor: 2.673

7.  The generation and characterization of novel Col1a1FRT-Cre-ER-T2-FRT and Col1a1FRT-STOP-FRT-Cre-ER-T2 mice for sequential mutagenesis.

Authors:  Minsi Zhang; David G Kirsch
Journal:  Dis Model Mech       Date:  2015-07-16       Impact factor: 5.758

8.  Mutationally-activated PI3'-kinase-α promotes de-differentiation of lung tumors initiated by the BRAFV600E oncoprotein kinase.

Authors:  J Edward van Veen; Michael Scherzer; Julia Boshuizen; Mollee Chu; Annie Liu; Allison Landman; Shon Green; Christy Trejo; Martin McMahon
Journal:  Elife       Date:  2019-08-27       Impact factor: 8.140

9.  Early differential responses elicited by BRAFV600E in adult mouse models.

Authors:  Pablo Lanuza-Gracia; Sergio Piñeiro-Hermida; Giuseppe Bosso; Merve Yilmaz; Rosa Serrano; Maria A Blasco
Journal:  Cell Death Dis       Date:  2022-02-10       Impact factor: 8.469

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.